

REGENERON PHARMACEUTICALS INC

Form 8-K

February 24, 2006

**Table of Contents**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 24, 2006**

**REGENERON PHARMACEUTICALS, INC.**

**(Exact name of registrant as specified in its charter)**

**New York**

**000-19034**

**133444607**

(State or other jurisdiction of  
incorporation)

(Commission File Number)

(I.R.S. Employer  
Identification Number)

**777 Old Saw Mill River Road, Tarrytown, New  
York**

**10591-6707**

(Address of principal executive offices)

(Zip Code)

**(914) 347-7000**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

- £ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - £ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - £ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - £ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 2.02 Results of Operations and Financial Condition

Item 9.01 Financial Statements and Exhibits

Exhibit Index

EX-99.A: PRESS RELEASE

---

**Table of Contents**

**Item 2.02 Results of Operations and Financial Condition**

On February 24, 2006, Regeneron Pharmaceuticals, Inc. announced its financial and operating results for the quarter and year ended December 31, 2005. A copy of the news release is attached hereto as Exhibit 99(a) and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits**

(c) Exhibits

99(a) Press Release of Regeneron Pharmaceuticals, Inc. dated February 24, 2006.

**Table of Contents**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REGENERON PHARMACEUTICALS,  
INC.

Dated: February 24, 2006

By: /s/ Stuart Kolinski  
Stuart Kolinski  
Vice President and General Counsel

3

---

**Table of Contents**

**Exhibit Index**

<b>Number</b>	<b>Description</b>
99(a)	Press Release of Regeneron Pharmaceuticals, Inc. dated February 24, 2006.

4